Browsing by Subject "Drug Industry"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Ethics in academia and the pharmaceutical industry(2023-03-14) Ghaemi, Nassir[Note: The slide presentation is not available from this event.] Many academics in medicine assume that they hold a higher ethical standard than the pharmaceutical industry. Some of this assumption has to do with the presumed not-for-profit nature of academia and the for-profit nature of the pharmaceutical industry. In this discussion, based on my personal experience in both settings, I will contrast and compare the ethical standards of the two groups. I will conclude that they are both ethically challenged with different drawbacks. In academia, the usual ethical problem is an excessive focus on power and prestige; in the pharmaceutical industry, as is well known, the ethical problem is the profit motive. Both are highly problematic, with different causes producing the same effects: the interests of the public are sacrificed for the desires of academics and the pharmaceutical industry. Different strengths also exist: Academic freedom of thought allows for free public expression of ideas, but, combined with tenure and the wish for inclusion in the status quo power structure, it leads to self-censorship and a conservatism of thinking. Academic life begins with freethinking and ends in group think. The pharmaceutical industry is much more open to new ideas because it is not attached to any idea; its main test is practical utility in the marketplace. Hence, it is, paradoxically, much more innovative than academia, but this innovation is only tied to commercial results. Many public health needs are ignored due to non-commercial potential.Item Institutional corruption & off-label drug use(2015-04-14) Rodwin, Marc A.Although sometimes reasonable, off-label drug use typically is unsupported by substantial evidence of effectiveness and safety. At the root of inappropriate off-label drug use lies institutional corruption of pharmaceutical practice. Institutional corruption involves perverse incentives for pharmaceutical firms, the lack of evaluation of off-label prescribing and conflicts of interest in the design, oversight, and reporting of clinical trials. Typical reform proposals such as increased sanctions for manufacturers, education for physicians, registration of clinical trials, and disclosure of conflicts of interest do not remove the source of the problem. The speaker explores alternative reform options. These include: 1) tracking off-label prescriptions to monitor the risks and benefits of off-label uses and the manufacturers' conduct; 2) changing pharmaceutical firm reimbursement to remove incentives to encourage off-label prescribing; and 3) independent clinical trials to evaluate drugs.